Literature DB >> 7692664

Secretogranin IV immunoreactivity in medullary thyroid carcinoma: an immunohistochemical study of 62 cases.

N Neuhold1, R Ullrich.   

Abstract

The presence and intracellular distribution of secretogranin IV (Sg IV) was determined on light microcop by the avidin-biotin peroxidase complex method with the monoclonal antibody (mAb) Hisl-19 in normal and hyperplastic C-cells, in 62 primary medullary thyroid carcinomas (MTCs) and in 17 MTCs in tissue from synchronous and/or metachronous lymph node metastases and in one liver metastasis. Sg IV immunoreactivity was present in almost all normal-looking and hyperplastic C-cells, in 59 of 62 (96%) of the primary tumours, in 18 of 26 (69%) lymph node metastases and in distant metastasis. Sg IV reactivity ranged from small foci of positive tumour cells to a reaction in virtually every malignant cell. Two different staining patterns were obvious: a granular cytoplasmic reactivity and a perinuclear cluster-type signal. Normal-appearing and hyperplastic C-cells were characterized by a uniform granular staining often coexisting with discrete cluster-type immunoreactivity. Various combinations of these staining patterns were observed in C-cell carcinomas. The pure cluster-type reactivity was restricted to malignant C cells and was not detected in normal-appearing and hyperplastic C-cells. In serial sections immunohistochemical results for Sg IV, calcitonin (Ct) and chromogranin A (Cg A) showed only partial correlation. Depending on the area of the tumour chosen, immunohistochemical reactivity for Ct and Cg A might not be demonstrated in neoplastic C-cells, while staining for Sg IV was retained. The amount and type of Sg IV reactivity of MTCs was not correlated with the biological behaviour of the tumours. These results indicate that mAb Hisl-19 is an excellent marker for normal, hyperplastic and neoplastic C-cells. MAb Hisl-19 is especially useful in cases with weak or questionable reactivity for Ct and Cg A. The switch from the granular pattern to the perinuclear distribution seems to indicate a malignant transformation of C-cells and might prove useful an an additional diagnostic clue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692664     DOI: 10.1007/bf01606581

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  13 in total

1.  Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma.

Authors:  H R Harach; E Wilander; L Grimelius; U Bergholm; P Westermark; S Falkmer
Journal:  Pathol Res Pract       Date:  1992-02       Impact factor: 3.250

2.  Reactivity of monoclonal islet cell antibodies on normal hyperplastic and neoplastic thyroid C-cells.

Authors:  N Neuhold; M Wimmer; O M Braun; G Horvat; K Krisch
Journal:  Cell Tissue Res       Date:  1989-08       Impact factor: 5.249

3.  Islet cell proteins defined by monoclonal islet cell antibody HISL-19.

Authors:  S Srikanta; K Krisch; G S Eisenbarth
Journal:  Diabetes       Date:  1986-03       Impact factor: 9.461

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Medullary thyroid carcinomas express chromogranin A and a novel neuroendocrine protein recognized by monoclonal antibody HISL-19.

Authors:  L J Deftos; W Woloszczuk; I Krisch; G Horvat; W Ulrich; N Neuhold; O Braun; A Reiner; S Srikanta; K Krisch
Journal:  Am J Med       Date:  1988-12       Impact factor: 4.965

6.  Ultrastructural localization of chromogranin: a potential marker for the electron microscopical recognition of endocrine cell secretory granules.

Authors:  I M Varndell; R V Lloyd; B S Wilson; J M Polak
Journal:  Histochem J       Date:  1985-09

7.  Immunocytochemical patterns of islet cell tumors as defined by the monoclonal antibody HISL-19.

Authors:  C Bordi; K Krisch; G Horvat; S Srikanta
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

8.  Immunohistochemical comparison of chromogranins A and B and secretogranin II with calcitonin and calcitonin gene-related peptide expression in normal, hyperplastic and neoplastic C-cells of the human thyroid.

Authors:  K W Schmid; R Kirchmair; D Ladurner; R Fischer-Colbrie; W Böcker
Journal:  Histopathology       Date:  1992-09       Impact factor: 5.087

9.  Diagnostic immunohistochemistry of neuroblastic tumors.

Authors:  G H Wirnsberger; H Becker; K Ziervogel; H Höfler
Journal:  Am J Surg Pathol       Date:  1992-01       Impact factor: 6.394

10.  Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation. Its application in diagnostic pathology.

Authors:  K Krisch; P Buxbaum; G Horvat; I Krisch; N Neuhold; W Ulrich; S Srikanta
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

View more
  4 in total

Review 1.  Secretogranin III: a diabetic retinopathy-selective angiogenic factor.

Authors:  Wei Li; Keith A Webster; Michelle E LeBlanc; Hong Tian
Journal:  Cell Mol Life Sci       Date:  2017-08-30       Impact factor: 9.261

Review 2.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

3.  The Pathology of Medullary Carcinoma of the Thyroid: Review of the Literature and Personal Experience on 62 Cases.

Authors:  Mauro Papotti; Daniela Sambataro; Carla Pecchioni; Gianni Bussolati
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

Review 4.  Role and function of granin proteins in diabetes mellitus.

Authors:  Zoltan Herold; Marton Doleschall; Aniko Somogyi
Journal:  World J Diabetes       Date:  2021-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.